European markets set to open lower as U.S. election result raises AI regulation concerns

European markets set to open lower as U.S. election result raises AI regulation concerns
AI concerns hit EU stocks

European stocks are set for a weaker start on Wednesday as investors assess the risk that Democratic control of both chambers of the U.S. Congress could tighten oversight of artificial intelligence. The mood is weighing most heavily on technology-related names and companies exposed to AI infrastructure spending, a key driver of this year's equity gains.

Highlights

  • STOXX 600 futures down 0.2% and FTSE 100 futures off 0.4% pre-market after U.S. Democrats secure both House and Senate majorities.
  • Investors reassess AI and data center growth prospects as stricter U.S. regulation could curb corporate spending, weighing on global equities.
  • Novo Nordisk beats third-quarter operating profit estimates and raises full-year forecasts, with healthcare sector attention on potential U.S. drug pricing regulation.

Futures point to weaker open

As reported by Reuters, futures tracking the STOXX 600 are down about 0.2% by 0639 GMT, after recovering part of a steeper 1.4% fall seen during Asian trading.

Contracts tied to Germany's DAX are also lower by about 0.2%, while futures on the UK's FTSE 100 are off 0.4%. The market reaction follows Tuesday's U.S. election outcome, in which Democrats win majorities in both the Senate and the House, including victories in traditionally conservative states such as South Carolina and Texas.

Investors are focusing on the possibility that stricter rules around AI and data centre construction could curb spending by companies developing the technology. That prospect is pressuring global equities as markets reassess the policy backdrop for one of the strongest investment themes of the year.

Tech and healthcare sectors in focus

Technology companies make up only about 7% of the STOXX index, but the sector posts the third-strongest gains so far this year, behind energy and chemicals. Demand for AI infrastructure has been a major support for those advances, leaving the group sensitive to any sign of heavier regulation.

Companies tied to AI-related capital spending, including equipment makers Siemens Energy and Schneider Electric, are also likely to draw attention as investors gauge the knock-on effect on infrastructure build-outs.

Novo Nordisk is meanwhile expected to stay in focus after the Wegovy maker reports third-quarter adjusted operating profit above expectations and raises its full-year sales and profit forecasts. The broader healthcare sector is also under scrutiny as investors weigh the possibility of increased U.S. regulation on drug pricing.

Our earlier article on U.S. AI data center build-outs highlighted how soaring costs, tighter funding conditions, and construction delays are raising doubts about how quickly new capacity can come online. We also noted that power constraints and local pushback are becoming additional bottlenecks, testing whether developers can deliver projects on time and keep investor confidence intact.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.